Affordable Access

Access to the full text

The Role of Interleukin-1 in the Pathogenesis of Cancer and its Potential as a Therapeutic Target in Clinical Practice

Authors
  • Litmanovich, Adi1, 2
  • Khazim, Khaled1, 2, 3
  • Cohen, Idan1, 2
  • 1 Bar Ilan University, The Azrieli Faculty of Medicine, Safed, Israel , Safed (Israel)
  • 2 Research Institute, Galilee Medical Center, Nahariya, Israel , Nahariya (Israel)
  • 3 Galilee Medical Center, Department of Nephrology and Hypertension, Nahariya, Israel , Nahariya (Israel)
Type
Published Article
Journal
Oncology and Therapy
Publisher
Springer Healthcare
Publication Date
Nov 28, 2018
Volume
6
Issue
2
Pages
109–127
Identifiers
DOI: 10.1007/s40487-018-0089-z
Source
Springer Nature
Keywords
License
Yellow

Abstract

Interleukin-1 (IL-1) has long been known to be a key mediator of immunity and inflammation. Its dysregulation has been implicated in recent years in tumorigenesis and tumor progression, and its upregulation is thought to be associated with many tumors. Overexpression of the IL-1 agonists IL-1α and IL-1β has been shown to promote tumor invasiveness and metastasis by inducing the expression of angiogenic genes and growth factors. IL-1 blockers such as anakinra and canakinumab are already approved and widely used for the treatment of some autoimmune and autoinflammatory diseases and are currently being tested in preclinical and human clinical trials for cancer therapy. In this paper we review the most recent discoveries regarding the association between IL-1 dysregulation and cancer and present the novel IL-1 blockers currently being tested in cancer therapy and their corresponding clinical trials.

Report this publication

Statistics

Seen <100 times